Related Experiment Video
Updated: Mar 24, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis
Priyanka Prakash1, Yong Zhou1, Hong Liang1
1Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas.
Abstract:
K-Ras is a membrane-associated GTPase that cycles between active and inactive conformational states to regulate a variety of cell signaling pathways. Somatic mutations in K-Ras are linked to 15-20% of all human tumors. K-Ras attaches to the inner leaflet of the plasma membrane via a farnesylated polybasic domain; however, the structural details of the complex remain poorly understood. Based on extensive (7.5 μs total) atomistic molecular dynamics simulations here we show that oncogenic mutant K-Ras interacts with a negatively charged lipid bilayer membrane in multiple orientations. Of these, two highly populated orientations account for ∼54% of the conformers whose catalytic domain directly interacts with the bilayer. In one of these orientation states, membrane binding involves helices 3 and 4 of the catalytic domain in addition to the farnesyl and polybasic motifs. In the other orientation, β-strands 1-3 and helix 2 on the opposite face of the catalytic domain contribute to membrane binding. Flexibility of the linker region was found to be important for the reorientation. The biological significance of these observations was evaluated by initial experiments in cells overexpressing mutant K-Ras as well as by an analysis of Ras-effector complex structures. The results suggest that only one of the two major orientation states is capable of effector binding. We propose that the different modes of membrane binding may be exploited in structure-based drug design efforts for cancer therapy.
Insights
Oncogenic mutant K-Ras binds to cell membranes in distinct orientations. Only one orientation facilitates effector binding, offering new avenues for cancer drug design targeting K-Ras membrane interactions.
Area of Science:
- Molecular Biology
- Biophysics
- Computational Chemistry
Background:
- K-Ras GTPase regulates cell signaling and is frequently mutated in human cancers.
- K-Ras membrane association is crucial for its function but structurally ill-defined.
- Understanding K-Ras membrane interactions is key to developing targeted cancer therapies.
Purpose of the Study:
- To elucidate the structural mechanisms of oncogenic K-Ras interaction with lipid membranes.
- To identify distinct K-Ras membrane-binding orientations and their functional implications.
Main Methods:
- Extensive atomistic molecular dynamics (MD) simulations (7.5 μs total).
- Analysis of K-Ras conformers interacting with a negatively charged lipid bilayer.
- Cellular experiments and analysis of Ras-effector complex structures.
Main Results:
- Oncogenic mutant K-Ras adopts multiple orientations when binding to lipid bilayers.
- Two major orientations were identified, with one involving helices 3 and 4, and the other involving β-strands 1-3 and helix 2.
- Linker region flexibility is critical for K-Ras reorientation.
- Only one of the identified membrane-binding orientations supports effector binding.
Conclusions:
- K-Ras exhibits diverse membrane-binding modes, influencing its signaling activity.
- The distinct K-Ras orientations provide potential targets for structure-based cancer drug design.
- Targeting specific K-Ras membrane-binding states could lead to novel therapeutic strategies.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
MAPK Signaling Cascades
Cell Polarization by Rho Proteins
Receptor Tyrosine Kinases

